Ovarian cander, Tubal carcinoma, Cervical cancer, Endometrial cancer, Primary peritoneal cancer, Liver cancer, Liver cirrhosis, Lung cancer, Gastric cancer, Colon cancer, Rectal cancer
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1. Age over20-years old. 2. Patients who voluntarily provided written consent to participate in this trial after having been thoroughly briefed and informed of its nature were eligible for enrollment.
Exclusion criteria
Exclusion criteria: 1. The patient who is higher than Serum bilirubin level 5mg/dL. 2. The patient that an infectious disease is strongly doubted by fever, abdominal symptom or high CRP level. 3. The patient with less than 1,000mL of gathered ascites (or pleural fluids). 4. The patient that hemolysis of the ascites is observed. 5. Other patients judged to be ineligible by the attending investigators.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Equivalency of the clinical manifestations improvement effect in the cryopreservation ascites group and the control group Inspection of the side effect reduction effect in the preservation cryopreservation ascites group. | — |
Secondary
| Measure | Time frame |
|---|---|
| In the preservation cryopreservation ascites group, 1. Change of various ascites components (pH, general biochemistry, cytokine) before and after the preservation. In the both groups, 1.Correlation of quantity of cytokine in the ascites and fever caused in the reinfusion. 2. Confirmation of safety by the examination for endotoxin. 3. Change of the blood test level before and after the treatment. | — |
Countries
Japan
Contacts
Tokyo Women's Medical University Department of Transfusion Medicine and Cell Processing